Equivalent healthcare resource use following either a long-acting steroid-eluting implant or repeat endoscopic surgery for chronic rhinosinusitis patients with nasal polyp recurrence: a real-world evidence study

Observed HCRU for CRSwNP patients after receiving the Implant was no different than after repeat ESS. Efficacy in avoiding subsequent interventions was likewise equivalent. Cost estimates suggest the Implant is lower cost than repeat ESS. Given similar impacts on HCRU/clinical efficacy and potential lower cost, the Implant may warrant consideration over repeat ESS as first-line intervention for CRSwNP patients with NP recurrence.